Converge Bio key facts
as of Oct 2026- Developer of a biotech platform designed to apply generative artificial intelligence to biological data for advancing drug discovery and development.
- Converge Bio is valued at approximately $90.0M as of Oct 2026, set at its early-stage round, Jan 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $30.5M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($25.0M) in Jan 2026.
- Notable investors include Bessemer Venture Partners, AWS Startups, TLV Partners, Vintage (Private Equity), AuroraAxis Capital — 6 tracked in total.
- 1 investment vehicle was formed to buy Converge Bio shares in the last 12 months, reporting $155K sold to 2 investors, per SEC Form D filings.
- Converge Bio has filed 1 Form D with the SEC, most recently Apr 2026 ($25.0M sold to 19 investors).
- Status: Privately Held (backing).
Valued at $90.0M at its early-stage round, Jan 2026. Nothing has traded since.
- ·Watch Converge Bio: the Monday email on marks, rounds and moves
Converge Bio funding rounds
1 roundsVehicles formed to buy Converge Bio shares
secondary demand · SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy Converge Bio shares, reporting $155K sold to 2 investors. Most recent filing Oct 2025.
Membership and data by Private Market View
Converge Bio valuation
Converge Bio was valued at $90 million at its early-stage round in Jan 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Converge Bio raised?
Converge Bio has raised $30.5 million across 1 recorded round since 2026. The largest was a $25 million Series A in Jan 2026.
Converge Bio has filed 1 Form D with the SEC, most recently in Apr 2026 ($25 million sold to 19 investors).
Institutional holders and vehicles
In the last 12 months, 1 investment vehicle was formed to buy Converge Bio shares, reporting $154,500 sold to 2 investors, per SEC Form D filings (most recent Oct 2025).
Converge Bio investors
6 investors are on record for Converge Bio, including Bessemer Venture Partners, AWS Startups, TLV Partners and Vintage (Private Equity). The Series A in Jan 2026 drew 2 investors.
About Converge Bio
Developer of a biotech platform designed to apply generative artificial intelligence to biological data for advancing drug discovery and development. The company's platform offers capabilities for molecule design, antibody engineering, target and biomarker identification, and protein yield optimization, enabling pharmaceutical and biotechnology companies to increase efficiency, accuracy, and consistency across drug development workflows.
- Industry
- Other Information Technology
- Sector
- Information Technology
- HQ
- Wilmington, DE, United States
- Founded
- 2024
- Employees
- 40
- Website
- converge-bio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.